

## CHECKLIST: To be completed by treating provider

The COVID-19 public health emergency has made clear that many hospitals and other institutions in Florida and elsewhere have insufficient drugs and other therapeutics to treat patients. The scarce drug allocation group, in conjunction with the COVID-19 CTW, has prepared this guidance document to be implemented in accordance with BHS Policy “Ethical Drug Shortage Management” (PHS ADM 09.00). These guidelines follow a utilitarian approach in trying to maximize benefits for the most people, consistent with scientific guidelines, and known literature.

Score	Criteria
1	<input type="checkbox"/> Body mass index (BMI) $\geq 35 - 44$
2	<input type="checkbox"/> Body mass index (BMI) $\geq 45$
1	<input type="checkbox"/> Chronic kidney disease
1	<input type="checkbox"/> Diabetes
1	<input type="checkbox"/> Immunosuppressive disease
1	<input type="checkbox"/> Currently receiving immunosuppressive treatment
1	<input type="checkbox"/> $\geq 65$ years of age
1	<input type="checkbox"/> Are $\geq 55$ years of age <b>AND</b> have cardiovascular disease, <b>OR</b> hypertension, chronic obstructive pulmonary disease/other chronic respiratory disease
1	<input type="checkbox"/> Are currently a healthcare worker that cares for COVID+ patients <b>AND</b> meets one of the criteria above. See reverse side <sup>Ex. 1</sup>
1	<input type="checkbox"/> Are 12 – 17 years of age weighing at least 89 lbs. <b>AND</b> have BMI $\geq 85$ th percentile for their age and gender based on CDC growth charts, <b>OR</b> sickle cell disease, <b>OR</b> congenital or acquired heart disease, <b>OR</b> neurodevelopmental disorders, for example, cerebral palsy, <b>OR</b> a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19), <b>OR</b> asthma, reactive airway or other chronic respiratory disease that requires daily medication for control

**Total** \_\_\_\_\_

<b>Patient Name:</b>	<b>First</b>	<b>Middle</b>	<b>Last</b>
<b>Patient DOB:</b>	____/____/____	<b>MRN:</b>	<b>Cerner</b> _____ <b>Allscripts</b> _____
<b>Date of Symptom Onset:</b>	____/____/____	<b>Date/Time of Appointment:</b>	____/____/____ : ____
<b>Reliable Patient Phone Number:</b>	( ) ____ - _____	<b>Ordering Provider:</b>	_____
<b>Reliable Patient Address:</b>	_____		
<b>Known Patient Allergies:</b>	_____		




**ADMINISTRATION CRITERIA**

Bamlanivimab or Casirivimab + Imdevimab should be administered to high-risk patients who are symptomatic as soon as possible after a positive result and within 10 days of symptom onset.

<b>The “HIGH-RISK” factors are defined as patients who meet the following criteria:</b>
<ul style="list-style-type: none"> <li>body mass index (BMI) ≥35</li> <li>chronic kidney disease</li> <li>diabetes</li> <li>immunosuppressive disease</li> <li>currently receiving immunosuppressive treatment</li> <li>≥65 years of age</li> <li>Are ≥55 years of age <b>AND</b> have cardiovascular disease, <b>OR</b> hypertension, chronic obstructive pulmonary disease/other chronic respiratory disease</li> <li>Are 12 – 17 years of age weighing at least 89 lbs. <b>AND</b> have BMI ≥85th percentile for their age and gender based on CDC growth charts, <b>OR</b> sickle cell disease, <b>OR</b> congenital or acquired heart disease, <b>OR</b> neurodevelopmental disorders, for example, cerebral palsy, <b>OR</b> a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19), <b>OR</b> asthma, reactive airway or other chronic respiratory disease that requires daily medication for control</li> <li>Live in an area where the ADI (Area Deprivation Index) is ≥8</li> </ul>

<b>The “EXCLUSION” criteria are defined as patients who meet the following:</b>
<ul style="list-style-type: none"> <li>hospitalized due to COVID-19</li> <li>requiring oxygen therapy due to COVID-19</li> <li>requiring an increase in baseline oxygen flow rate due to COVID-19 or those on chronic oxygen therapy due to underlying non COVID-19 related comorbidities</li> <li>exhibiting symptoms greater than a 10 day time period</li> <li>have a suspected co-existing viral, fungal, or bacterial infection</li> </ul>

**BASED ON SUPPLY VOLUME**

Less Supply  More Supply	<b>Phase 1</b>	Patients with a score 3 or greater
	<b>Phase 2</b>	Patients with a score 2 or greater
	<b>Phase 3</b>	Patients with a score 1 or greater

\*Phases to be reviewed frequently based on volume of drug available\*

Ex. 1 Health Care Worker	<ul style="list-style-type: none"> <li>Definition for health care workers for the purposes of COVID-19 anti-body therapy, we recommend using the same definition: Physicians (MD/DO); Advanced Practice Providers (NP/PA); Nurses (RN/LPN); Medical Assistants; Medical Technicians; Respiratory Therapists; Rehab Services; Spiritual Care; Pharmacists; Laboratory Technicians processing human samples; Phlebotomists; Radiology Technicians; Social Workers; Case Managers; Behavioral Health Providers if seeing patients in-person; Home Health Agency Personnel/Technicians including workers at non-medical home care agencies who work in client homes; Environmental Services Technicians; Food Service Technicians; Dieticians/nutritionists; Mortuary Services; Security.</li> <li>This list is not exhaustive but providers within one of these groups must have or be at risk for contact with patients or patient samples.</li> <li>Reference: Preliminary Plan for Phased Implementation of COVID-19 Vaccination for the State of Colorado</li> </ul>
--------------------------	---